GAUSH MEDITECH (02407): Subsidiary Gaosh Tailiang Receives International Medical Device Quality Management System Certification

Stock News
2025/09/29

GAUSH MEDITECH (02407) announced that its subsidiary, Gaosh Tailiang Medical Technology Co., Ltd. (Gaosh Tailiang), has officially received the ISO 13485:2016/EN ISO 13485:2016 medical device quality management system certification issued by DEKRA (Certificate No.: 6214501).

The certification comprehensively covers the complete process of design, development, production, and sales of intraocular lenses for treating cataract and presbyopia patients, as well as their supporting intraocular lens implantation systems.

DEKRA, established in 1925, is a globally leading independent non-listed professional inspection, testing, and certification organization covering extensive industry sectors. ISO 13485 is a medical device industry-specific quality management system standard issued by the International Organization for Standardization (ISO), focusing on "patient-centered" risk management and full-process quality control. It serves as a core compliance basis recognized by global medical device regulatory authorities, including China's NMPA, EU CE, and US FDA.

Obtaining this certification indicates that the company has established a quality management system covering the entire product lifecycle including design and development, production, inspection, and after-sales service, ensuring products meet regulatory requirements and continuous improvement.

The acquisition of this important qualification demonstrates the company's determination to enhance its quality management system and marks that the company has achieved international standard capabilities in medical device quality management, risk control, and compliance operations. This further establishes a solid foundation for the company's expansion into international markets.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10